Vliyanie terapii polovymi gormonami na sostoyanie molochnykh zhelez u zhenshchin s defitsitom androgenov i fibrozno-kistoznoy bolezn'yu

Cite item

Full Text



  1. Сметник В.П. Красота зрелого возраста. Status Praesents, 2011.
  2. Harvie M, Hooper L, Howell AH. Central obesity and breast cancer risk: a systematic review. Obes Rev 2003; 4 (3): 157-73.
  3. Hulca BS, Moorman PG. Reprint of Breast cancer: hormones and other risk factors. Maturitas 2008; 61: 203-13.
  4. Fournier F. Clavel-Chapelon. Unicual risks for breast cancer associated with different hormone replacement therapies results from the E3N cohort study. Breast Cancer Res Treat 2008; 107 (1): 103-11.
  5. Fabre A, Fournier A, Mesrine S et al. Oral progestagens before menopause and breast cancer risk. Br J Cancer 2007; 96 (5): 841-4.
  6. Alfred O, Muecka, Seegera H, Kai-J. Use of dydrogesterone in hormone replacement therapy. Maturitas 2009: 65S, S51-S60.
  7. Радзинский В.Е., Калинченко С.Ю., Апетов С.С. Терапия андрогенами в гинекологической практике. Вестн. РУДН. 2010; 6: 196-204.
  8. Braunstein GD, Sundwall DA, Kate M et al. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: randomized placebo-controlled trial. Arch Intern Med 2005; 165: 1582-9.
  9. Buster JE, Kingsberg SA, Brown C et al. Testosterone patch for low sexual desire in surgically menopausal women: A randomized trial. Obstet Gynecol 2005; 105: 944-52.
  10. Davis SR, Bouchard C, Kroll R et al. The effect of a testosterone transdermal system on hypoactive sexual desire disorder in postmenopausal women not receiving systemic estrogen therapy, the aphrodite study. 82nd Annual Meeting of the Endocrine Society; Boston USA, 2006.
  11. Somboonporn W, Davis SR. Postmenopausal testosterone therapy and breast cancer risk. Maturitas 2004; 49: 267-75.
  12. Labrie F, Luu-The V, Labrie C et al. Endocrine and intracrine sources of androgens in women: Inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev 2003; 24: 152-82.
  13. Gammon MD, Thompson WD. Polycystic ovaries and the risk of breast cancer. Am J Epidemiol 1991; 134: 818-24.
  14. Burgess HE, Shousha S. An immunohistochemical study of the long-term effects of androgen administration on female-to-male transsexual breast: A comparison with normal female breast and male breast showing gynaecomastia. J Pathol 1993; 170: 37-43.
  15. Dimitrakakis C, Jones RA, Liu A, Bondy CA. Breast cancer incidence in postmenopausal women using testosterone in addition to usual hormone therapy. Menopause 2004; 11: 531-5.
  16. Сотникова Л.С. Мастопатия. Новые аспекты в лечении. 2011; с. 6-14.
  17. Радзинский В.Е, Калинченко С.Ю., Апетов С.С. Синдром дефицита андрогенов у женщин. Вестн. РУДН. 2010; 6: 266-76.
  18. Bachmann GA, Bancroft J, Braunstein G et al. Female androgen insufficiency: the Princeton consensus statement on definition, classification and assessment. Fertil Steril 2002; 77: 660-5.
  19. Guay A, Munarriz R, Jacobson J et al. Serum androgen levels in healthy premenopausal women with and without sexual dysfunction: Part A. Serum androgen levels in women aged 20-49 years with no complaints of sexual dysfunction, kit. J Impot Res 2004; 16: 112-20.
  20. Davison SL, Bell R, Donath S et al. Androgen levels in adult females: Changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab 2005; 90: 3847-53.
  21. Zumoff B, Strain GW, Miller LK, Rosner W. Twenty-four-hour mean plasma testosterone concentration declines with age in normal premenopausal women. J Clin Endocrinol Metab 1995; 80: 1429-30.
  22. Singh AB, Lee ML, Sinha-Hikim I et al. Pharmacokinetics of a testosterone gel in healthy postmenopausal women. J Clin Endocrinol Metab 2006; 91: 136-44.
  23. Braunstein GD. The Endocrine Society Clinical Practice Guideline and The North American Menopause Society position statement on androgen therapy in women: Another one of Yogi's forks. J Clin Endocrinol Metab 2007; 92: 4091-3.
  24. Hofling M, Carlstrom K, Svane G et al. Different effects 'of tibolone and continuous combined estrogen plus progestogen hormone therapy on sex hormone binding globulin and free testosterone levels an association with mammographic density. Gynecol Endocrinol 2005; 20: 110-5.
  25. Hofling M, Hirschberg AL, Skoog L et al. Testosterone inhibits estrogen/progestogen-induced breast cell proliferation in postmenopausal women. Menopause 2007; 14: 183-90.
  26. Burger HG. Should testosterone be added to estrogen-progestin therapy for breast protection? Menopause 2007; 14: 159-62.

Copyright (c) 2012 Apetov S.S., Kalinchenko S.Y., Agafonova A.V., Sotnikova L.S.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies